Solithromycin for the treatment of community-acquired bacterial pneumonia
Diego Viasus1, Oscar Ramos1, Leidy Ramos1
1a Faculty of Medicine, Health Sciences Division , Hospital Universidad del Norte and Universidad del Norte , Barranquilla , Colombia.
Introduction:
Community-acquired pneumonia is a major public health problem worldwide. In recent years, there has been an increase in the frequency of resistance to the antimicrobials such as β-lactams or macrolides which have habitually been used against the causative pathogens. Solithromycin, a next-generation macrolide, is the first fluoroketolide with activity against most of the frequently isolated bacteria in community-acquired pneumonia, including typical and atypical bacteria as well as macrolide-resistant Streptococcus pneumoniae. Areas covered: A detailed assessment of the literature relating to the antimicrobial activity, pharmacokinetic/pharmacodynamic properties, efficacy, tolerability and safety of solithromycin for the treatment of community-acquired bacterial pneumonia Expert commentary: Recent randomized controlled phase II/III trials have demonstrated the equivalent efficacy of oral and intravenous solithromycin compared with fluoroquinolones in patients with lower mild-to-moderate respiratory infections, and have shown that systemic adverse events are comparable between solithromycin and alternative treatments. However, studies of larger populations which are able to identify infrequent adverse events are now needed to confirm these findings. On balance, current data supports solithromycin as a promising therapy for empirical treatment in adults with community-acquired bacterial pneumonia.
Insights
Solithromycin, a novel fluoroketolide antibiotic, shows promise for treating community-acquired pneumonia. It is effective against resistant bacteria and demonstrates comparable efficacy and safety to existing treatments.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Community-acquired pneumonia (CAP) presents a significant global health challenge.
- Increasing antimicrobial resistance to traditional agents like beta-lactams and macrolides complicates CAP treatment.
- Pathogens causing CAP include typical and atypical bacteria, with growing resistance in Streptococcus pneumoniae.
Purpose of the Study:
- To assess the antimicrobial activity, pharmacokinetics, pharmacodynamics, efficacy, tolerability, and safety of solithromycin.
- To evaluate solithromycin's potential as a treatment for community-acquired bacterial pneumonia (CABP).
Main Methods:
- Literature assessment of solithromycin's properties and clinical trial data.
- Review of randomized controlled phase II/III trials comparing solithromycin to fluoroquinolones.
- Analysis of efficacy and safety data in patients with mild-to-moderate lower respiratory tract infections.
Main Results:
- Solithromycin exhibits activity against common CAP pathogens, including macrolide-resistant Streptococcus pneumoniae.
- Oral and intravenous solithromycin demonstrated equivalent efficacy to fluoroquinolones in phase II/III trials.
- Systemic adverse events were comparable between solithromycin and alternative treatments.
Conclusions:
- Solithromycin is a promising next-generation macrolide (fluoroketolide) for CABP treatment.
- Further large-scale studies are needed to identify rare adverse events.
- Current data supports solithromycin's role in empirical treatment for adult CABP.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...